Association between Hashimoto’s thyroiditis and cholelithiasis: a retrospective cohort study in Taiwan

Chien-Hua Chen,1,2,3,4 Cheng-Li Lin,5,6 Chia-Hung Kao7,8,9

ABSTRACT

Objective To investigate the relation of Hashimoto’s thyroiditis (HT) to cholelithiasis and cholecystectomy in a retrospective population-based study.

Setting Cohort study.

Participants We identified 1268 patients aged ≥20 years with HT between 2000 and 2010 as the study cohort.

Primary and secondary outcome measures Patients without HT were randomly selected from a database and propensity-matched with the study cohort at a 1:4 ratio according to age, sex, comorbidities and year of the index date to measure the incidence of cholelithiasis and cholecystectomy.

Results The cumulative incidence of cholelithiasis was higher in the HT cohort than that in the non-HT cohort (log-rank test, p<0.001), with a 1.91-fold higher risk of cholelithiasis (95% CI 1.58 to 2.33) after adjustment for comorbidities. The age-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients aged ≥50 years (adjusted HR=2.59, 95% CI 1.33 to 5.03). The sex-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for women (aHR=1.99, 95% CI 1.63 to 2.44). Compared with those in the non-HT cohort, patients with HT without (aHR=1.95, 95% CI 1.02 to 1.61) compared with those in the non-HT cohort, patients with HT had a higher risk of cholecystectomy (aHR=1.28, 95% CI 1.02 to 1.61).

Conclusions Inability to obtain information on several potential confounding factors and misclassification of important covariates are the major limitations of the study. Our study indicates HT per se was associated with the development of cholelithiasis, which has been validated by the association between cholecystectomy and HT. Surveys and health education on cholelithiasis in women aged ≥50 years with HT should be considered by clinicians, and further prospective research should be done on this topic.

INTRODUCTION

Cholelithiasis involves gallbladder stones, intrahepatic stones (IHS) and common bile duct (CBD) stones. Among the subtypes of cholelithiasis, the reported proportion of gallbladder stones was approximately 85%, that of CBD stones was 19% and that of IHS was 11%–15%.1–3 The prevalence of cholelithiasis varies with ethnicity, environment, lifestyle and dietary habits. The reported prevalence of cholelithiasis in the USA ranged between 10% and 12%, whereas that in Taiwan ranged between 5% and 10%.4–6 Of individuals with gallbladder stones, 20% were reported to experience biliary symptoms in their lifetime, and approximately 1%–2% of patients with gallbladder stones require surgery annually.7 Nearly 10%–15% of patients with CBD stones were reported to harbour concomitant gallbladder stones, which were considered to be the origin of stone migration, and the remaining patients (85%–90%) were considered to present de novo stones in the CBD.8 Approximately 10% of patients with CBD stones remained asymptomatic; however, only 2% of patients with CBD stones exhibited no signs of elevated liver function tests, dilated CBD, jaundice or pancreatitis.9 Therefore, the extraction of CBD stones is recommended if possible, regardless of whether they are symptomatic.10 More than 50% of
patients with IHS experience suppurative cholangitis or cholangiocarcinoma if the stones are not completely retrieved. In brief, cholelithiasis is one of the common morbidities among the adult population, and it is a major public health concern because of its potential development to cholecystitis, cholangitis, pancreatitis and biliary tract cancers.

Hashimoto’s thyroiditis (HT) often leads to hypothyroidism, resulting from chronic destruction of the thyroid gland by an autoimmune process. The reported prevalence of HT in Western countries was approximately 0.1%–5%, and women exhibited a 10-fold to 20-fold higher risk of harbouring HT. The diagnosis of HT is mainly based on the presence of circulating antibodies to thyroperoxidase or thyroglobulin, reduced echogenicity on thyroid ultrasound, and manifestations of compression of organs adjacent to the thyroid gland. The utilisation of radioactive iodine or cytological examinations of thyroid aspirate was rarely applied in clinical practice. Moreover, HT was more prevalent in middle-aged individuals (between 45 and 65 years). HT is reported to be both the most common endocrine disorder and the most common cause of hypothyroidism.

Hypothyroidism is a well-known risk factor for cholelithiasis, particularly for gallstone diseases (GSD). However, not all patients will develop hypothyroidism, and they sometimes present euthyroid or hyperthyroid features. It has been reported that either euthyroidism or subclinical hypothyroidism in children with HT frequently evolved towards clinical hypothyroidism, whereas those presenting with overt hypothyroidism always had definitive resolution of hyperthyroid to evolve towards euthyroidism or hypothyroidism. Furthermore, the association between HT and cholelithiasis has never been discussed in the literature. In this study, we hypothesised that HT per se is associated with an increased risk of cholelithiasis. We conducted a nationwide population-based cohort study by analysing data from the Longitudinal Health Insurance Research Database (LHID2000) of the Taiwan National Health Insurance Research Database (NHIRD) to determine the association between HT and the subsequent development of cholelithiasis, either symptomatic or asymptomatic, in considering the confounding factors of hypothyroidism and hyperthyroidism. Furthermore, we also assessed the association between HT and cholecystectomy to diminish surveillance bias and to validate the aforementioned association between HT and cholelithiasis.

METHODS

Data source

This was a nationwide cohort study using the LHID2000 of the NHIRD, which contains claims data of the beneficiaries of the National Health Insurance (NHI) programme in Taiwan. In brief, this NHI programme began on 1 March 1995, and covers approximately 99% of the 23.74 million residents of Taiwan. The details of the NHI programme and LHID2000 have been thoroughly addressed in previous studies. Diseases were coded according to the 2001 International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

Patient and public involvement statement

Figure 1 shows the selection process of the participants in the two study cohorts. This study recruited patients with newly diagnosed HT (ICD-9 code 245.2) who were aged ≥20 years from LHID2000 between 1 January 2000 and 31 December 2010. The date of diagnosis of HT was defined as the index date. The control cohort was randomly selected from LHID2000 and included patients without a history of HT who were propensity-matched with the case cohort at a ratio of 4:1. Non-HT control patients were frequency-matched with respect to age group (every 5-year span); sex; comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, chronic obstructive pulmonary disease (COPD), obesity, stroke, coronary artery disease (CAD), hepatitis B virus, hepatitis C virus and inflammatory bowel disease (IBD); and index year of HT diagnosis. The index date for control patients was randomly appointed based on the month and day with the same index year of the matched patients. We also considered hyperthyroidism and hypothyroidism as comorbidities. Patients with a history of cholelithiasis (ICD-9-CM code 574) and those with incomplete information on age or sex at baseline were excluded from both the HT and non-HT cohorts. Each patient was examined from the index date until the occurrence of cholelithiasis, death, withdrawal from the NHI programme or the end of 31 December 2011. Individuals who emigrated out of Taiwan or who died are withdrawn from the NIH programme. Both identified cause-specific and non-cause-specific deaths were included in the analysis, whereas deaths were censored if the cause could not be identified.

Statistical analysis

The distributions of age, sex and comorbidities between the HT and non-HT cohorts were compared and examined using the \( \chi^2 \) test. The mean ages (SDs) and mean follow-up period (SDs) between the cohorts were compared and tested using Student’s t-test. The Kaplan-Meier method was used to compare the cumulative incidence of cholelithiasis events and survival between the cohorts, and the log-rank test was used to examine the differences. Cholelithiasis incidence density rates were estimated by dividing the number of cholelithiasis events by the number of person-years for each risk factor, and the results were then stratified by age, sex, and presence or absence of a comorbidity. Univariable and multivariable Cox proportional hazard regression models were used to assess the risk of cholelithiasis associated with HT. The HRs and 95% CIs were estimated using the Cox model, which were adjusted for age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension,
COPD, CAD, IBD, hyperthyroidism and hypothyroidism. Multivariable Cox proportional hazard regression models were also used to assess the association between cholecystectomy and HT. All data analyses were performed using SAS V.9.4. The significance level was set at two-tailed p<0.05.

**RESULTS**

The study examined an HT cohort of 1268 patients and a non-HT cohort of 5021 patients (table 1). The HT and non-HT cohorts were well matched for age, sex and comorbidities. The mean ages in the HT and non-HT cohorts were 42.7±13.6 and 42.4±13.8 years, respectively. Most patients were older than 35 years (65.5%) and were women (90.0%). Excluding hyperthyroidism and hypothyroidism, the top three comorbidities according to the order of frequency in these study cohorts were hypertension (18.0%), hyperlipidaemia (17.8%) and CAD (10.8%). It was noted that hyperthyroidism and hypothyroidism were more prevalent in the HT cohort than in the non-HT cohort. Of the 367 patients of the HT cohort with a history of hyperthyroidism, 171 (46.6%) patients had history of Graves’ disease (GD) before evolving to HT. Of the 96 patients of non-HT cohort with a history of hyperthyroidism, 41 (42.7%) patients had history of GD.

Figure 2 shows the cumulative incidences (100%) of cholelithiasis in the HT and the non-HT cohorts during the follow-up period. The cumulative incidence of cholelithiasis was higher in the HT cohort than that in the non-HT cohort (log-rank test, p<0.001). The average follow-up duration was 5.91±3.24 years for the HT cohort and 5.88±3.22 years for the non-HT cohort.

Table 2 presents the incidence of and risk factors for cholelithiasis. The overall incidence density rates of cholelithiasis in the HT and non-HT cohorts were 3.74 and 2.24 per 1000 person-years, respectively. Compared with patients without HT, those with HT were associated with an increased risk of cholelithiasis (adjusted HR (aHR)=1.91, 95% CI 1.58 to 2.33) after adjustment for age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, COPD, CAD, IBD, hyperthyroidism and hypothyroidism. HT was found to be consistently associated with the development of cholelithiasis (aHR=1.96, 95% CI 1.60 to 2.40) after we excluded the 171 patients with a history of GD before evolving to HT to avoid enrolling a more varied autoimmune thyroid disease group into the HT cohort (data not shown). Compared with patients aged ≤34 years, the risk of cholelithiasis was 2.14-fold higher in those aged 35–49 years (95% CI 1.67 to 2.75) and 4.33-fold higher in those aged ≥50 years (95% CI 3.33 to 5.64). Multivariable analysis for comorbidities revealed that hyperlipidaemia (aHR=1.39, 95% CI 1.15 to 1.68), diabetes (aHR=1.55, 95% CI 1.22 to 1.97), liver cirrhosis (aHR=2.27, 95% CI 1.07 to 4.85), CAD (aHR=2.04, 95% CI 1.67 to 2.50) and IBD (aHR=3.21, 95% CI 1.87 to 5.52) remained the independent risk factors for cholelithiasis.

**Figure 1** Selection process of the participants in the two study cohorts.
Table 3 presents the comparison of the cholelithiasis incidence densities between patients with and without HT stratified by demographic characteristics and the presence or absence of a comorbidity. The age-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients aged ≥50 years (aHR=2.59, 95% CI 1.33 to 5.03). The sex-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for women (aHR=1.99, 95% CI 1.63 to 2.44). The comorbidity-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients without comorbidities (aHR=2.29, 95% CI 1.77 to 2.95) or with comorbidities (aHR=1.38, 95% CI 1.08 to 1.76).

Table 1  Demographic characteristics and comorbidities of cohorts with and without Hashimoto’s thyroiditis

| Variable                        | Hashimoto’s thyroiditis | P values |
|---------------------------------|-------------------------|----------|
|                                | No  | Yes  |                      |
| Age, year                       | n=5021 | n=1268 |                      |
| ≤34                             | 1743 (34.7) | 437 (34.5) | 0.98 |
| 35–49                           | 1886 (37.6) | 476 (37.5) |          |
| 50+                             | 1392 (27.7) | 355 (28.0) |          |
| Mean±SD*                        | 42.4 (13.8) | 42.7 (13.6) | 0.57 |
| Sex                             |                                    | 0.97 |
| Female                          | 4520 (90.0) | 1141 (90.0) |          |
| Male                            | 501 (9.98) | 127 (10.0) |          |
| Comorbidity                     |                                    |      |
| Hyperlipidaemia                 | 881 (17.6) | 226 (17.8) | 0.82 |
| Diabetes                        | 302 (6.01) | 80 (6.31) | 0.69 |
| Liver cirrhosis                 | 22 (0.44) | 9 (0.71) | 0.22 |
| Alcohol-related illness         | 98 (1.95) | 30 (2.37) | 0.35 |
| Hypertension                    | 886 (17.7) | 228 (18.0) | 0.78 |
| Chronic obstructive pulmonary disease | 379 (7.55) | 102 (8.04) | 0.55 |
| Obesity                         | 166 (3.31) | 44 (3.47) | 0.77 |
| Stroke                          | 44 (0.88) | 14 (1.10) | 0.45 |
| Coronary artery disease         | 524 (10.4) | 137 (10.8) | 0.70 |
| Hepatitis B virus               | 183 (3.64) | 49 (3.86) | 0.71 |
| Hepatitis C virus               | 69 (1.37) | 20 (1.58) | 0.58 |
| Inflammatory bowel disease      | 26 (0.52) | 9 (0.71) | 0.41 |
| Hyperthyroidism                 | 96 (1.91) | 367 (28.9) | <0.001 |
| Hypothyroidism                  | 26 (0.52) | 277 (21.9) | <0.001 |

χ² test.  
*t-test.

Compared with those in the non-HT cohort, patients with HT without (aHR=1.95, 95% CI 1.53 to 2.49) and with (aHR=1.94, 95% CI 1.51 to 2.49) thyroxine treatment were associated with a higher risk of cholelithiasis (table 4).

Table 5 shows the overall incidence of cholecystectomy and estimated HRs according to HT status by Cox proportional hazard regression model. Compared with those in the non-HT cohort, patients with HT had a higher risk of cholecystectomy (aHR=1.28, 95% CI 1.02 to 1.61). Similarly, HT was consistently associated with the risk of cholecystectomy (aHR=1.33, 95% CI 1.05 to 1.69) after we excluded the 171 patients with a history of GD from the HT cohort (data not shown).

**DISCUSSION**

We observed that the prevalence of HT was higher in women (90.0%) and in patients older than 35 years (65.5%), with a mean age of 42.7±13.6 years. Furthermore, the age-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients aged ≥50 years, and the sex-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for women (table 3). These findings reflect the concerns regarding the survey of cholelithiasis in women aged ≥50 years with HT. Furthermore, the reasons for no relationship between male gender and age <50 years with increased cholelithiasis incidence in patients with HT might be due to the smaller study populations of men (n=127) and the smaller case number of cholelithiasis (44 of 913), respectively.

Excluding hyperthyroidism and hypothyroidism, our findings were consistent with the literature to demonstrate that the top three common comorbidities associated with HT were hypertension, hyperlipidaemia and...
| Variable                  | Event | Person-years | Rate† | Crude HR (95% CI) | Adjusted HR‡ (95% CI) |
|--------------------------|-------|--------------|-------|-------------------|----------------------|
| Hashimoto's thyroiditis | No    | 66           | 29508 | 2.24              | 1.00                 |
|                         | Yes   | 28           | 7489  | 3.74              | 1.67 (1.41 to 1.99)***| 1.91 (1.58 to 2.33)***|
| Age, year                |       |              |       |                   |                      |
| ≤34                      | 13    | 13649        | 0.95  | 1.00              | 1.00                 |
| 35–49                    | 31    | 14158        | 2.19  | 2.30 (1.79 to 2.95)***| 2.14 (1.67 to 2.75)***|
| 50+                      | 50    | 9190         | 5.44  | 5.71 (4.51 to 7.23)***| 4.33 (3.33 to 5.64)***|
| Sex                      |       |              |       |                   |                      |
| Female                   | 83    | 33763        | 2.46  | 1.00              | 1.00                 |
| Male                     | 11    | 3234         | 3.40  | 1.38 (1.08 to 1.72)* | 1.07 (0.84 to 1.37) |
| Comorbidity              |       |              |       |                   |                      |
| Hyperlipidaemia          |       |              |       |                   |                      |
| No                       | 62    | 30792        | 2.01  | 1.00              | 1.00                 |
| Yes                      | 32    | 6205         | 5.16  | 2.56 (2.17 to 3.03)***| 1.39 (1.15 to 1.68)***|
| Diabetes                 |       |              |       |                   |                      |
| No                       | 81    | 34947        | 2.32  | 1.00              | 1.00                 |
| Yes                      | 13    | 2050         | 6.34  | 2.74 (2.17 to 3.44)***| 1.55 (1.22 to 1.97)***|
| Liver cirrhosis          |       |              |       |                   |                      |
| No                       | 93    | 36889        | 2.52  | 1.00              | 1.00                 |
| Yes                      | 1     | 110          | 9.07  | 3.60 (1.66 to 7.82)** | 2.27 (1.07 to 4.85)***|
| Alcohol-related illness  |       |              |       |                   |                      |
| No                       | 92    | 36423        | 2.53  | 1.00              | 1.00                 |
| Yes                      | 2     | 574          | 3.49  | 1.38 (0.79 to 2.40) | –                    |
| Hypertension             |       |              |       |                   |                      |
| No                       | 68    | 30822        | 2.21  | 1.00              | 1.00                 |
| Yes                      | 26    | 6175         | 4.21  | 1.91 (1.60 to 2.28)***| 0.68 (0.55 to 1.00)  |
| COPD                     |       |              |       |                   |                      |
| No                       | 85    | 34669        | 2.45  | 1.00              | 1.00                 |
| Yes                      | 9     | 2328         | 3.87  | 1.58 (1.20 to 2.07)***| 0.92 (0.70 to 1.20)  |
| Obesity                  |       |              |       |                   |                      |
| No                       | 92    | 36011        | 2.55  | 1.00              | 1.00                 |
| Yes                      | 2     | 986          | 2.03  | 0.79 (0.46 to 1.38) | –                    |
| Stroke                   |       |              |       |                   |                      |
| No                       | 93    | 36784        | 2.53  | 1.00              | 1.00                 |
| Yes                      | 1     | 213          | 4.69  | 1.86 (0.85 to 4.03) | –                    |
| CAD                      |       |              |       |                   |                      |
| No                       | 69    | 33530        | 2.06  | 1.00              | 1.00                 |
| Yes                      | 25    | 3468         | 7.21  | 3.50 (2.93 to 4.19)***| 2.04 (1.67 to 2.50)***|
| Hepatitis B virus        |       |              |       |                   |                      |
| No                       | 90    | 35843        | 2.51  | 1.00              | 1.00                 |
| Yes                      | 4     | 1154         | 3.47  | 1.38 (0.93 to 2.05) | –                    |
| Hepatitis C virus        |       |              |       |                   |                      |
| No                       | 92    | 36509        | 2.52  | 1.00              | 1.00                 |
| Yes                      | 2     | 488          | 4.10  | 1.63 (0.94 to 2.82) | –                    |

Continued
CAD (table 1). Hypothyroidism can lead to atherosclerosis and arterial stiffness through increased production of total and low-density lipoprotein (LDL) cholesterol, increased levels of apolipoprotein B and elevated levels of homocysteine. Furthermore, the increase in total and LDL cholesterol and apolipoprotein B is proportional to the severity of hypothyroidism. Furthermore, an autoimmune process and chronic inflammation in HT have been supposed to be directly related to the development of cardiovascular disease. HT and GD are generally believed to share a number of common aetiological factors, although they may have different phenotypes of the thyroid functions. It is more frequent for GD to spontaneously evolve to HT, while the development of GD from HT was quite rare. Consistent with the literature, approximately 46.6% of patients with HT with a history of hyperthyroidism ever presented the diagnosis of GD in our study.

| Variable | Event | Person-years | Rate† | Crude HR (95% CI) | Adjusted HR‡ (95% CI) |
|----------|-------|--------------|-------|------------------|----------------------|
| IBD      | No    | 92           | 36785 | 2.50             | 1.00                 |
|          | Yes   | 2            | 211   | 9.47             | 3.79 (2.18 to 6.57)***| 3.21 (1.87 to 5.52)***|
| Hyperthyroidism | No   | 87           | 34335 | 2.53             | 1.00                 |
|          | Yes   | 7            | 2662  | 2.63             | 1.94 (1.60 to 2.36)***| 0.77 (0.56 to 1.06)  |
| Hypothyroidism | No   | 88           | 35359 | 2.49             | 1.00                 |
|          | Yes   | 6            | 1638  | 3.66             | 1.47 (1.06 to 2.04)*  | 0.76 (0.54 to 1.07)  |

Crude HR, relative HR.
*P<0.05, **p<0.01, ***p<0.001.
†Incidence rate, per 1000 person-years.
‡Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, COPD, CAD, IBD, hyperthyroidism and hypothyroidism.

Table 3 Comparison of the cholelithiasis incidence densities between patients with and without Hashimoto’s thyroiditis by demographic characteristics and presence or absence of a comorbidity

| Variables | Hashimoto’s thyroiditis |          |          |          | Crude HR (95% CI) | Adjusted HR‡ (95% CI) |
|-----------|-------------------------|----------|----------|----------|------------------|----------------------|
|           | No                      | Person-years | Event | Person-years | Rate† | Crude HR (95% CI) | Adjusted HR‡ (95% CI) |
| Age, years| ≤49                     | 33       | 22137   | 1.49     | 11    | 5670 1.94 | 1.30 (1.04 to 1.63)*  | 1.29 (0.57 to 2.92)  |
|           | 50+                     | 33       | 7371    | 4.48     | 17    | 1819 9.35 | 2.09 (1.56 to 2.80)***| 2.59 (1.33 to 5.03)***|
| Sex       | Female                  | 58       | 26916   | 2.15     | 25    | 6847 3.65 | 1.69 (1.41 to 2.03)***| 1.99 (1.63 to 2.44)***|
|           | Male                    | 8        | 2592    | 3.09     | 3     | 642   4.67 | 1.51 (0.86 to 2.66)   | 1.33 (0.63 to 2.79)  |
| Comorbidity| No                     | 22       | 18054   | 1.22     | 7     | 2491 2.81 | 2.07 (1.58 to 2.71)***| 2.29 (1.77 to 2.95)***|
|           | Yes                     | 44       | 11454   | 3.84     | 21    | 4998 4.20 | 1.18 (0.92 to 1.50)   | 1.38 (1.08 to 1.76)  |

Crude HR, relative HR.
*P<0.05, **p<0.01, ***p<0.001.
†Incidence rate, per 1000 person-years.
‡Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism.
common stone type encountered in the elderly population.\textsuperscript{4,5} The association between cholelithiasis and hypercholesterolaemia remains controversial; however, a low high-density lipoprotein cholesterol level and hypertriglyceridaemia are associated with an increased risk of stones.\textsuperscript{4} Diabetes, associated with insulin resistance, can lead to increased cholesterol saturation in the bile and impaired gallbladder motility.\textsuperscript{29,30} Liver cirrhosis is associated with the development of black pigment stones because of altered pigment secretion, impaired gallbladder contraction and increased oestrogen levels.\textsuperscript{4} CAD and cholelithiasis may share a common pathophysiological mechanism of increasing cholesterol deposition in the atherosclerotic plaque and cholesterol saturation in the bile.\textsuperscript{31,32} IBD can cause cholesterol stones by reducing bile acid reabsorption in the terminal ileum, and the absorbed bile acid can cause pigment stones by dissolving bilirubin and increasing its absorption in enterohepatic cycling.\textsuperscript{33} However, a possible surveillance bias was raised because patients with comorbidities are more likely to get diagnosed with incidental cholelithiasis than patients without these morbidities. The inclusion of asymptomatic cholelithiasis in the outcome group could inadvertently tag more indications of abdominal imaging, and therefore lead to unexpected associations between some comorbidities with cholelithiasis.

Our results reveal that HT was closely related to the development of cholelithiasis, after adjustment for age, sex, hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism. HT, Hashimoto’s thyroiditis.

### Table 4 Incidence and HR of cholelithiasis compared between non-HT cohort and patients with HT with and without thyroxine (T4) treatment

| Variables                  | n   | Event | Person-years | Rate† | Crude HR (95% CI) | Adjusted HR‡ (95% CI) |
|----------------------------|-----|-------|-------------|-------|-----------------|----------------------|
| Non-HT controls            | 5021| 66    | 29508       | 2.24  | 1 (reference)   | 1 (reference)        |
| HT without T4 treatment    | 556 | 12    | 3276        | 3.66  | 1.64 (1.29 to 2.09)*** | 1.95 (1.53 to 2.49)*** |
| HT with T4 treatment       | 712 | 16    | 4213        | 3.8   | 1.70 (1.37 to 2.10)*** | 1.94 (1.51 to 2.49)*** |

Crude HR, relative HR.

*P<0.05, **p<0.01, ***p<0.001.

†Incidence rate, per 1000 person-years.

‡Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism.

### Table 5 Overall incidence of cholecystectomy (per 1000 person-years) and estimated HRs according to Hashimoto’s thyroiditis status by Cox proportional hazard regression model

| Variables                  | Hashimoto’s thyroiditis | Incidence |
|----------------------------|-------------------------|-----------|
|                            | No (n=5021)             | Yes (n=1268) |
| Cholecystectomy            | 29678                   | 7572      |
| Person-years               | 5.91±3.22               | 5.98±3.23 |
| Follow-up time (years), mean±SD | 0.92                  |
| Event, n                  | 30                      | 7         |
| Rate                      | 1.01                    | 0.92      |
| Crude HR (95% CI)         | 1 (reference)           | 0.91 (0.74 to 1.14) |
| Adjusted HR (95% CI)†     | 1 (reference)           | 1.28 (1.02 to 1.61) |

*P<0.05

†Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism.
The use of thyroxine does not seem to ameliorate the increased incidence of cholelithiasis for HT since patients with HT with (aHR=1.94, 95% CI 1.51 to 2.49) and without (aHR=1.95, 95% CI 1.53 to 2.49) thyroxine treatment were similarly associated with a higher risk of cholelithiasis than those in the non-HT cohort and their aHRs were comparable (table 4). These findings support that the association between HT and cholelithiasis might not simply be relevant to the thyroid function. Our study has several strengths. First, this is the first population-based cohort study on the association between HT and cholelithiasis. Additionally, we used a longitudinal database with a 12-year observation period for a large cohort size of 1 000 000 residents to demonstrate the association between HT and the subsequent development of cholelithiasis. Second, the Taiwan NHI programme covers healthcare for more than 99% of the residents of Taiwan under a single-payer system, and all the insurance claims for medical reimbursement have shown a substantial concordance in the literature. Therefore, the present findings reveal an association between HT and cholelithiasis based on the real situations of Taiwan with a profoundly large sample size and can represent generalisability in Taiwan. However, more studies are required to clarify the association, which may vary with ethnicity and environment. Our study also has several limitations. First, the evidence derived from a retrospective cohort study is generally of lower methodological quality than that from randomised trials since the retrospective cohort study is subject to many biases related to the necessary adjustments for confounding factors. Many of these factors could not be ascertained at all from the insurance claims database (eg, postmenopausal hormone use, diet, coffee, alcohol, smoking and so on), and some could only be ascertained partially (eg, obesity instead of body mass index) even though we have used the diagnosis of COPD and alcohol-related illness as replacements for the habits of smoking and alcohol consumption, respectively. Second, we could not validate the diagnosis of HT and cholelithiasis by individually reviewing the medical records. However, the NHI programme is managed by the Taiwanese government, and all insurance claims are audited based on standard diagnostic criteria for medical reimbursement. Medical providers are fined and face administrative sanction if the diagnostic coding and claims data are incorrect. Third, the 171 patients with a history of GD before evolving to HT might belong to a heterogeneous autoimmune thyroid disease group, rather than conventionally defined HT, since they often had positive antibodies and chronic inflammatory features in sonography that are difficult to differentiate from HT. However, HT was consistently associated with the risk of cholelithiasis or cholecystectomy even though we have excluded the 171 patients with a history of GD from the HT cohort. Fourth, the association between HT and cholelithiasis might be skewed by surveillance bias since patients with HT would get more opportunities for abdominal imaging studies, or the presence of cholelithiasis was not recorded in the insurance claims data because no treatment was required. However, the association has been supported by the association between cholecystectomy and HT in our study, although asymptomatic cholelithiasis and cholecystectomy might be different entities. Finally, the definite pathophysiology and the causal relationship for the association between HT and cholelithiasis could not be ascertained in this observational study and more studies are required to clarify the relationship. However, the association could not be simply explained by hypothyroidism. HT per se might be associated with the development of cholelithiasis, and was supported by our findings that the association persisted in multivariable Cox proportional hazard regression model after controlling for the confounding factors, including hyperthyroidism and hypothyroidism. Furthermore, with comparable aHRs, patients with HT with and without thyroxine treatment were similarly associated with a higher risk of cholelithiasis than those in the non-HT cohort. In conclusion, our population-based cohort study demonstrated HT per se was associated with the development of cholelithiasis, particularly in women aged ≥50 years. The risk of cholelithiasis increased with the follow-up time after a diagnosis of HT. Surveys and health education on cholelithiasis in women aged ≥50 years with HT should be considered by clinicians and further prospective research should be done on this topic. The aforementioned association has been supported by the association between cholecystectomy and HT. However, inability to obtain information on several potential confounding factors and misclassification of important covariates are major limitations of the study.
Funding  This work was supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University Hospital (DMR-107-192), Academia Sinica Stroke Biosignature Project (BM10701010021), MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005-), Tseng-Lien Lin Foundation, Taichung, Taiwan, and Katsuzo and Kiyoko Aoshima Memorial Funds, Japan.

Competing interests  None declared.

Patient consent  Not required.

Ethics approval  The NHIRD encrypts personal patient information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH-104-REC-2-115-CR2). The IRB also specifically waived the consent requirement.

Provenance and peer review  Not commissioned; externally peer reviewed.

Data sharing statement  The data set used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The MOHW must approve our application to access these data. Any researcher interested in accessing this data set can submit an application form to the MOHW requesting access. Please contact the staff of Ministry of Health and Welfare (MOHW). The MOHW must approve our application to access the data. If approved, an application form will be sent to the researchers. The MOHW must also be informed of any data to be used.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Su CH, Lui WY, P'eng FK. Relative prevalence of gallstone diseases in Taiwan. A nationwide cooperative study. *Dig Dis Sci* 1992;37:764–8.

2. Kim MH, Lim BC, Myung SJ, et al. Epidemiological study on Korean gallstone disease: a nationwide cooperative study. *Dig Dis Sci* 1996;41:1674–83.

3. Park YH, Park SJ, Jang JY, et al. Changes in patterns of gallstone disease in Korea. *World J Surg* 2004;28:206–10.

4. Shafter EA. Gallstone disease: epidemiology of gallbladder stone disease. *Best Pract Res Clin Gastroenterol* 2006;20:981–96.

5. Chen CY, Lu CL, Huang YS, et al. Age is one of the risk factors in developing gallstone disease in Taiwan. *Age Ageing* 1996;27:437–41.

6. Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of gallstone disease in an adult population of Taiwan: an epidemiological survey. *J Gastroenterol Hepatol* 2006;21:1737–43.

7. Ransosch DF, Gracie WA, Wolfenson LB, et al. Prophylactic cholecystectomy or expectant management for silent gallstones. *Rheumatology* 2014;53:1279–90.

8.ears of various durations. *J Intern Med* 1995;237:403–9.

9. Abrahamsson H. Autoimmune thyroid diseases in Taiwan. A nationwide cooperative study. *Dig Dis Sci* 2003:33:799–810.

10. Laukkanen J, Sand J, Autio V, et al. Bile duct stone procedures are more frequent in patients with hypothyroidism. A large, registry-based, cohort study in Finland. *Scand J Gastroenterol* 2010;45:708–13.

11. Andreini JP, Prigge WF, Ma C, et al. Vesicles and mixed micelles in hypothroid rat bile before and after thyroid hormone treatment: evidence for a vesicle transport system for biliary cholesterol secretion. *J Lipid Res* 1994;35:1405–12.

12. Field FJ, Albright E, Mathur SN. Effect of dietary cholesterol on biliary cholesterol content and bile flow in the hypothyroid rat. *Gastroenterology* 1986:91:297–304.

13. Inkinen J, Sand J, Arvola P, et al. Direct effect of thyroxine on pig sphincter of Oddi contractility. *Dig Dis Sci* 2001;46:182–6.

14. Laukkanen J, Sand J, Auttomiäki S, et al. Mechanism of the prelaxing effect of thyroxine on the sphincter of Oddi. *Scand J Gastroenterol* 2002;37:667–73.

15. Hernández-Rodríguez J, Tan CD, Rodríguez ER, et al. Single-organ gallbladder vasculitis: characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 61 patients. *Medicine* 2014;93:405–13.

16. Koppisetti S, Jenigiri B, Terron MP, et al. Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review. *Dig Dis Sci* 2008;53:2922–903.

17. Wu CS, Lai MS, Gau SS, et al. Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. *PLoS One* 2014;9:e112257.

18. Cheng CL, Lee CH, Chen PS, et al. Validation of acute myocardial infarction cards in the national health insurance research database in Taiwan. *J Epidemiol* 2014;24:500–7.